UPDATE - Wyeth, Progenics drug misses goal in Phase 3 study (at Reuters)
yahoo.com     May 23, 2008            

NEW YORK, May 22 (Reuters) - Wyeth (WYE.N: ) and Progenics Pharmaceuticals Inc (PGNX.O: ) said on Thursday that an intravenous form of their Relistor drug failed to meet its main goal in a late-stage study for addressing gastrointestinal issues following surgery. The Phase 3 study, which also... [read full story]                    


View all news articles about*:
Pharmaceuticals Progenics
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Progenics Pharmaceuticals Reports Second Quarter 2008 Results

redorbit.com     Aug 8, 2008   1 related          

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the second quarter and first half of 2008. Revenues for the second quarter ended June 30, 2008 totaled $28.6 million compared to $25.5...                    

comments

Media Advisory - BMO Capital Markets to Host 8th Annual Focus On Healthcare Conference (PR Newswire)

yahoo.com     Jul 30, 2008   2 related          

BMO Capital Markets, the investment and corporate banking arm of BMO Financial Group , will hold its eighth annual two-day conference, Focus On Healthcare, Tuesday, August 5 and Wednesday, August 6, at the Millennium Broadway...                    

comments

                   

Cancer Vaccine Contenders Lurk Among the Casualties

tmcnet.com     Jul 28, 2008   8 related          

Between the negative Phase III news on Oxford BioMedica plc's TroVax and the positive Phase III news on Biovest International Inc.'s BiovaxID, it's been a big month for cancer vaccines. But despite all the failures and amid all...                    

comments

Generic Heartburn at Wyeth (at Motley Fool)

yahoo.com     Jul 25, 2008          

By Brian Orelli July 25, 2008 Comments (0) Wyeth (NYSE: WYE) has a serious case of generic-induced heartburn that's not likely to go away any time soon. Revenue from its heartburn drug Protonix dropped 59% year over year after...                    

comments